Literature DB >> 29655914

Importance of cynomolgus monkeys in development of monoclonal antibody drugs.

Kazuhide Iwasaki1, Yasuhiro Uno2, Masahiro Utoh2, Hiroshi Yamazaki3.   

Abstract

Animal species used in the preclinical studies for development of monoclonal antibody (mAb) drugs are surveyed in this review. Relevant animal species for preclinical studies of mAb candidates are those express desired epitope of mAb candidates. Cynomolgus monkeys cross-react with mAb drugs much higher than other animal species commonly used in preclinical studies such as absorption, distribution, metabolism and excretion (ADME), efficacy, and toxicity studies, for development of new drugs. Moreover, plasma exposure of the mAb drugs in humans is predicted well from the exposure in the monkeys, and the placental transfer of immunoglobulin G (IgG, all the mAb drugs contain IgG) from mother to fetus is similar between humans and the monkeys from a viewpoint of time course and plasma level of IgG transferred. These observed findings indicate that the monkeys are the most suitable animal species used in the ADME and toxicity studies for development of new mAb drugs.
Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cynomolgus monkeys; Experimental animals; Monoclonal antibody drugs; Neonatal Fc receptor; New drug development; Preclinical studies

Mesh:

Substances:

Year:  2018        PMID: 29655914     DOI: 10.1016/j.dmpk.2018.02.003

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  7 in total

Review 1.  Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation.

Authors:  Kenta Haraya; Haruka Tsutsui; Yasunori Komori; Tatsuhiko Tachibana
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-22

2.  Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.

Authors:  Kenta Haraya; Tatsuhiko Tachibana
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

Review 3.  Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.

Authors:  Dale E Johnson
Journal:  Int J Mol Sci       Date:  2018-11-21       Impact factor: 5.923

Review 4.  The Cynomolgus Macaque MHC Polymorphism in Experimental Medicine.

Authors:  Takashi Shiina; Antoine Blancher
Journal:  Cells       Date:  2019-08-26       Impact factor: 6.600

5.  Justification for species selection for pharmaceutical toxicity studies.

Authors:  Helen Prior; Richard Haworth; Briony Labram; Ruth Roberts; Alison Wolfreys; Fiona Sewell
Journal:  Toxicol Res (Camb)       Date:  2020-11-24       Impact factor: 3.524

6.  Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors.

Authors:  Richard Graveline; Morad Haida; Carolyne Dumont; Dominic Poulin; Florence Poitout-Belissent; Rana Samadfam; Sven Kronenberg; Franziska Regenass-Lechner; Rodney Prell; Marie-Soleil Piche
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

7.  Exploring the Definition of "Similar Toxicities": Case Studies Illustrating Industry and Regulatory Interpretation of ICH S6(R1) for Long-Term Toxicity Studies in One or Two Species.

Authors:  Helen Prior; David O Clarke; David Jones; Eleni Salicru; Melissa M Schutten; Fiona Sewell
Journal:  Int J Toxicol       Date:  2022-04-18       Impact factor: 2.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.